RIKEN’s precision model algorithms designed to predict COVID-19 outcomes using THL’s patient data and BCP’s BC|INSIGHT. RIKEN is Japan’s largest comprehensive research institution encompassing a network of world class research centres and institutes across Japan
26 January, 2021
Lytix Biopharma AS has received FDA clearance to initiate a Phase II clinical trial in the US designed to assess the efficacy of its lead candidate LTX-315, a first-in-class oncolytic peptide, in several solid tumor types.
26 January, 2021
OSLO/LONDON, JANUARY 20 2021: EXACT THERAPEUTICS AS (“EXACT-Tx” or the “Company”), a clinical stage precision medicine company today announced a collaboration with GE Healthcare to develop an innovative ultrasound probe to be used in forthcoming studies using Acoustic Cluster Therapy (ACT®) across multiple disease conditions.
25 January, 2021
The fully launched MAH and priority review pathways from the NMPA (National Medical Products Administration) is stimulating new demand in China for 2021
23 January, 2021
A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.
22 January, 2021
The topic of this month’s newsletter from Drug Discovery Today is “Structural Biology”.
18 January, 2021
Mission: Cure is a coalition of patients, doctors, researchers and entrepreneurs who are committed to advancing new therapies and cures for currently untreatable diseases. Their primary disease focus is on chronic pancreatitis, a rare inflammatory condition that affects over a million people across the globe. This partnership will combine Healx’s AI and drug discovery expertise with Mission: Cure’s disease knowledge and preclinical, clinical and patient networks to identify and advance the world’s first effective treatment for chronic pancreatitis.
13 January, 2021
Exploratory research project aims to develop novel protein expression systems via cell reprogramming
12 January, 2021
Success also de-risks the use of ILP-drug candidates in other medical indications, including the company’s inflammatory bowel disease program.
12 January, 2021